Acoramidis

A medication for the treatment of transthyretin amyloidosis

Acoramidis is a pharmaceutical drug used in the treatment of transthyretin amyloidosis, a rare and progressive disease characterized by the accumulation of misfolded transthyretin proteins in various tissues and organs. This condition can lead to severe complications, including cardiomyopathy and neuropathy. Acoramidis works by stabilizing the transthyretin protein, thereby preventing its misfolding and subsequent deposition as amyloid fibrils.

Mechanism of Action

Acoramidis functions as a transthyretin stabilizer. Transthyretin is a transport protein that carries thyroxine and retinol-binding protein bound to retinol. In transthyretin amyloidosis, mutations in the transthyretin gene lead to the production of unstable protein variants that misfold and aggregate into amyloid fibrils. Acoramidis binds to the thyroxine-binding sites of transthyretin, stabilizing the tetrameric form of the protein and preventing its dissociation into monomers, which are prone to misfolding.

Clinical Use

Acoramidis is indicated for the treatment of both hereditary and wild-type transthyretin amyloidosis. It is particularly beneficial in patients with cardiomyopathy associated with transthyretin amyloidosis, as it helps to reduce the progression of cardiac dysfunction and improve quality of life.

Administration

Acoramidis is administered orally, typically in the form of tablets. The dosage and treatment regimen depend on the severity of the disease and the patient's overall health status. Regular monitoring of transthyretin levels and cardiac function is recommended during treatment.

Side Effects

Common side effects of Acoramidis include gastrointestinal disturbances, such as nausea and diarrhea, as well as fatigue and headache. In some cases, patients may experience more severe adverse effects, necessitating dose adjustment or discontinuation of therapy.

Development and Approval

Acoramidis was developed as part of ongoing efforts to find effective treatments for transthyretin amyloidosis, a condition with limited therapeutic options. Clinical trials demonstrated its efficacy in stabilizing transthyretin and slowing disease progression, leading to its approval by regulatory agencies for use in patients with this condition.

Related pages

• Transthyretin amyloidosis
• Cardiomyopathy
• Neuropathy
• Protein misfolding

Acoramidis chemical structure